UBI集團訊息
聯生藥UB-421臨床二期試驗結果獲選為 2017 CROI LATE BREAKER報告
聯生藥UB-421臨床二期試驗結果獲選為 2017 CROI LATE BREAKER報告
全部產業訊息
-
View More 
UBP Receives Nomination from Biologics Manufacturing Asia (BMA)UBI集團訊息UBP Receives Nomination from Biologics Manufacturing Asia (BMA)
UBP Receives Nomination from Biologics Manufacturing Asia (BMA) -
-
-
View More 生醫中心就位 拚當亞太重鎮
-
View More 
United Biopharma Submitted completed anti-HIV therapeutic mAb UB-421 Phase II Clinical Trial Report, to TFDA for reviewUBI集團訊息United Biopharma Submitted completed anti-HIV therapeutic mAb UB-421 Phase II Clinical Trial Report, to TFDA for review
United Biopharma Submitted completed anti-HIV therapeutic mAb UB-421 Phase II Clinical Trial Report, to TFDA for review -
-
View More 聯生藥抗乳癌抗體藥物UB-921申請一期臨床試驗
-
View More 
UBP announces UB-421 research data at Cold Spring Harbor Laboratory Conference on HIV/AIDS ResearchUBI集團訊息UBP announces UB-421 research data at Cold Spring Harbor Laboratory Conference on HIV/AIDS Research
UBP announces UB-421 research data at Cold Spring Harbor Laboratory Conference on HIV/AIDS Research -
View More 聯亞生技受食藥署邀請演講 ： 國際蛋白質藥物發展趨勢
-
View More 
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing FacilityUBI集團訊息UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility
UBP Obtained the Building Use Permit for its Industry-scale Protein Drug Manufacturing Facility -
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
TAG相關標籤
POPULAR熱門文章
